Study:
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer`s Disease Who Are Apolipoprotein E4 Carriers.
Rationale:
n/a
Purpose:
This is a multicenter, double-blind, placebo controlled, randomized, outpatient, multiple
dose study in male and female patients ages 50 to less than 89 years with mild to moderate
AD. Approximately 200 study sites in the US and Canada will be involved. Patients will be
randomized to receive either bapineuzumab or placebo. Each patient`s participation will
last approximately 1.5 years.
Bapineuzumab is a humanized monoclonal antibody, which binds to and clears beta amyloid
peptide, and is designed to provide antibodies to beta amyloid directly to the patient.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Alzheimer`s Disease |
Drug: Bapineuzumab
Drug: Placebo Control |
Phase 3 |
Verified by
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
March, 2012
Sponsored by: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Information provided by: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
ClinicalTrials.gov identifier: NCT00575055
Study Type: Interventional
Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada 89106
United States
n/a